Poorly differentiated thyroid carcinoma: An incubating entity

Frontiers in Endocrinology

Volumn 3, Issue JUN, 2012, Pages

  Sadow, Peter M ^a,b   Faquin, William C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874446964     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00077     Document Type: Article

References (33)

1. Akslen, L. A., and LiVolsi, V. A. (2000). Prognostic sig-nifcance of histologic grading compared with sub-classifcation of papillary thyroid carcinoma. Cancer 88, 1902-1908.
2. Asioli, S., Erickson, L. A., Righi, A., Jin, L., Volante, M., Jenkins, S., Papotti, M., Bussolati, G., and Lloyd, R. V. (2010). Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod. Pathol. 23, 1269-1278.
3. Bongiovanni, M., Sadow, P. M., and Faquin, W. C. (2009). Poorly differentiated thyroid carcinoma: a cytologic-histologic review. Adv. Anat. Pathol. 16, 283-289.
4. Carcangiu, M. L., Zampi, G., and Rosai, J. (1984). Poorly differentiated ("insular") thyroid carcinoma. Am. J. Surg. Pathol. 8, 655-668.
5. Chakravarty, D., Santos, E., Ryder, M., Knauf, J. A., Liao, X. H., West, B. L., Bollag, G., Kolesnick, R., Thin, T. H., Rosen, N., Zanzonico, P., Larson, S. M., Refetoff, S., Ghossein, R., and Fagin, J. A. (2011). Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thy roid cancers w ith conditional BRAF activation. J. Clin. Invest. 121, 4700-4711.
6. Dettmer, M., Schmitt, A., Steinert, A., Steinert, H., Moch, H., Komminoth, P., and Perren, A. (2012). Poorly differentiated oncocytic thyroid carcinoma - diagnostic implications and outcome. Histopathology 60, 1045-1051.
7. Dettmer, M., Schmitt, A., Steinert, H., Haldemann, A., Meili, A., Moch, H., Komminoth, P., and Perren, A. (2011). Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed? Am. J. Surg. Pathol. 35, 1866-1872.
8. Dobashi, Y., Sugimura, H., Sakamoto, A., Mernyei, M., Mori, M., Oyama, T., and Machinami, R. (1994). Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn. Mol. Pathol. 3, 9-14.
9. Donghi, R., Longoni, A., Pilotti, S., Michieli, P., Della Porta, G., and Pierotti, M. A. (1993). Gene p53 muta-t ions are rest ricted to poorly differentiate d and undif-ferentiated carcinomas of the thyroid gland. J. Clin. Invest. 91, 1753-1760.
10. Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S. H., and Koeffer, H. P. (1993). High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 91, 179-184.
11. Garcia-Rostan, G., and Sobrinho-Simões, M. (2010). Poorly differentiated thyroid carcinoma: an evolving entity. Diagn. Histopathol. 17, 114-123.
12. Hiltzik, D., Carlson, D. L., Tuttle, R. M., Chuai, S., Ishill, N., Shaha, A., Shah, J. P., Singh, B., and Ghossein, R. A. (2006). Poorly differentiated thyroid carcinomas defned on the basis of mitosis and necrosis: a clinico-pathologic study of 58 patients. Cancer 106, 1286-1295.
13. Kakudo, K., Bai, Y., Liu, Z., Li, Y., Ito, Y., and Ozaki, T. (2012). Classifcation of thyroid follicular cell tumors: with special reference to borderline lesions. Endocr. J. 59, 1-12.
14. Lavra, L., Ulivieri, A., Rinaldo, C., Dominici, R., Volante, M., Luciani, E., Bartolazzi, A., Frasca, F., Soddu, S., and Sciacchitano, S. (2009). Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. J. Pathol. 218, 66-75.
15. Malaguarnera, R., Vella, V., Vigneri, R., and Frasca, F. (2007). p53 family proteins in thyroid cancer. Endocr. Relat. Cancer 14, 43-60.
16. Nambiar, A., Pv, S., Susheelan, V., and Kuriakose, M. A. (2011). The concepts in poorly differentiated carcinoma of the thyroid: a review article. J. Surg. Oncol. 103, 818-821.
17. Nikiforov, Y. E. (2004). Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr. Pathol. 15, 319-327.
18. Nikiforov, Y. E., and Nikiforova, M. N. (2011). Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol. 7, 569-580.
19. Nucera, C., Porrello, A., Antonello, Z. A., Mekel, M., Nehs, M. A., Giordano, T. J., Gerald, D., Benjamin, L. E., Priolo, C., Puxeddu, E., Finn, S., Jarzab, B., Hodin, R. A., Pontecorvi, A., Nose, V., Lawler, J., and Parangi, S. (2010). B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc. Natl. Acad. Sci. U.S.A. 107, 10649-10654.
20. Quiros, R. M., Ding, H. G., Gattuso, P., Prinz, R. A., and Xu, X. (2005). Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103, 2261-2268.
21. Ricarte-Filho, J. C., Ryder, M., Chitale, D. A., Rivera, M., Heguy, A., Ladanyi, M., Janakiraman, M., Solit, D., Knauf, J. A., Tuttle, R. M., Ghossein, R. A., and Fagin, J. A. (2009). Mutational profle of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 69, 4885-4893.
22. Rivera, M., Ricarte-Filho, J., Patel, S., Tuttle, M., Shaha, A., Shah, J. P., Fagin, J. A., and Ghossein, R. A. (2010a). Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumornecrosis): a clinicopathologic and molecular study. Hum. Pathol. 41, 172-180.
23. Rivera, M., Ricarte-Filho, J., Tuttle, R. M., Ganly, I., Shaha, A., Knauf, J., Fagin, J., and Ghossein, R. (2010b). Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathy-roid extension. Thyroid 20, 1085-1093.
24. Sakamoto, A., Kasai, N., and Sugano, H. (1983). Poorly differentiated carcinoma of the thyroid. A clinico-pathologic entity for a high-risk group of papillary and follicular carcinomas of the thyroid gland. Cancer 52, 1849-1855.
25. Siegel, R., and Jemal, A. (2012). Cancer Facts and Figures 2012. Atlanta, GA: American Cancer Society, 10.
26. Siironen, P., Hagström, J., Mäenpää, H. O., Louhimo, J., Heikkilä, A., Heiskanen, I., Arola, J., and Haglund, C. (2010). Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients. Oncology 79, 400-408.
27. Sobrinho-Simões, M., Albores-Saavedra, J., Tallini, G., Santoro, M., Volante, M., Pilotti, S., Carcangiu, M. L., Papotti, M., Matias-Guiu, X., Guiter, G. E., Zakowski, M., and Sakamoto, A. (2004). "Poorly differentiated carcinoma," in World Health Organization Classifcation of Tumors: Pathology and Genetics of Tumours of Endocrine Organs, eds R. A. DeLellis, R. V. Lloyd, P. U. Heitz, and C. Eng (Lyon: IARC Press), 73-76.
28. Sobrinho-Simões, M., Sambade, C., Fonseca, E., and Soares, P. (2002). Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. Int. J. Surg. Pathol. 10, 123-131.
29. Tallini, G. (2011). Poorly differentiated thyroid carcinoma. Are we there yet? Endocr. Pathol. 22, 190-194.
30. Thompson, L. D. (2011). Hyalinizing trabecular adenoma of the thyroid gland. Ear Nose Throat J. 90, 416-417.
31. Volante, M., Collini, P., Nikiforov, Y. E., Sakamoto, A., Kakudo, K., Katoh, R., Lloyd, R. V., LiVolsi, V. A., Papotti, M., Sobrinho-Simoes, M., Bussolati, G., and Rosai, J. (2007). Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am. J. Surg. Pathol. 31, 1256-1264.
32. Volante, M., and Papotti, M. (2010). Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classifcation of endocrine tumours. Endocr. Pathol. 21, 1-6.
33. Volante, M., Rapa, I., Gandhi, M., Bussolati, G., Giachino, D., Papotti, M., and Nikiforov, Y. E. (2009). RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J. Clin. Endocrinol. Metab. 94, 4735-4741.